Newsletter | December 7, 2021

12.07.21 -- Expanding The Boundaries Of Sub-Cutaneous Injections

Industry Insights
Expanding The Boundaries Of Sub-Cutaneous Injections

As the field of biologics increases its focus on identifying new diseases to target and novel constructs to treat them, innovative administration devices are once again in the spotlight.

Navigating CMC Requirements For Accelerated Development

CMC activities are critical to quickly and efficiently moving promising new drug products to market. Careful planning and early integration of an effective CMC strategy contributes to project success.

3 Tips For Purifying His-Tagged Proteins

Tags simplify purification and enable scientists to use standard protocols while also improving the yield, purity, and solubility of the protein of interest.

Enabling Broader Adoption Of Process Intensification In Biopharma

PI is becoming increasingly well-understood and its utility is evolving to meet specific manufacturer needs, from product development to manufacturing, whether approached stepwise or end-to-end.

Introducing N-1 Perfusion To Intensify The Seed Train At A Higher Starting Density

A high-density N-1 seed culture can improve your fed-batch process by allowing you to seed the production (N) bioreactor at a higher starting density or to replace a large N-1 bioreactor.

SARS-CoV-2 Viral RNA Extraction From Human Saliva Samples With NAB Nanosep Centrifugal Devices

In this study we evaluate the performance of the Pall NAB Nanosep centrifugal device for the isolation of SARS-CoV-2 viral RNA from human saliva samples spiked with heat inactivated virus using reagents (RCOM1 and RCOM2) from two commercially available kits for extraction of viral RNA.

Embrace Molecule Complexity With Optimized Expression Technologies

Explore the needs of more complex candidates, through case studies that demonstrate the range of expression capabilities across mammalian and microbial derived molecules.

Accelerating Drug Discovery With Artificial Intelligence

It typically takes about 5 years and requires the synthesis of 4,000 or more compounds to develop a new lead candidate. BIOVIA Dassault Systèmes has launched an initiative that leverages AI and machine learning techniques to significantly reduce cost and timelines for discovering new lead candidates while at the same time to increase their success rate in the clinic.

Most Popular News
Life Science Leader Magazine

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.